130 likes | 146 Views
As a leading service provider in the field of biological research and drug discovery, Creative Biolabs provides fast & elaborate therapeutic antibody discovery, drug candidates screening and vaccine development services to help combat this outbreak.<br>https://sars-cov-2.creative-biolabs.com/novel-coronavirus-sars-cov2.htm
E N D
SARS-CoV-2 Outbreak Process End of 2019 - Wuhan, China January 30, 2020 - PHEIC January, 2020 - Named 2019-nCoV February 11, 2020 - Named SARS-CoV-2 Now – Spread in over 200 countries (WHO)
Coronaviruses Family The SARS-CoV-2 virus that causes COVID-19 belongs to the Coronaviridae family. Birds and Mammals Mammals SARS-CoV-2
SARS-CoV-2 Structure Spike Glycoprotein (S) Get the virus into the cell M-Protein Virus germination and envelope formation Hemagglutinin-esterase (HE) May facilitate the virus to initially adsorb the cell membrane RNA and N Protein N protein is related to the formation of nucleocapsid in RNA genome E-Protein The smallest and most mysterious Envelope
SARS-CoV-2 Life Cycle 1 4 Release Fusion ACE2 2 Replicate 3 Assembly
SARS-CoV-2 Treatment Strategies 1 2 3 Use existing molecular libraries and databases to screen for molecules that may have a therapeutic effect on SARS-CoV-2. Screen the existing broad-spectrum antiviral drugs. Develop specific drugs based on the genomic information and pathological characteristics of SARS-CoV-2.
Object of Specific Drugs 3-1. Target to the Host Enhance immune response - such as the release of interferon. Block the signal pathways required for virus replication. Target viral and cell surface receptor proteins (ACE2). • • •
Object of Specific Drugs 3-2. Target to SARS-CoV-2 Block the virus’s binding to human cell receptors or inhibiting the virus’self-assembly process - target to the structural proteins of the virus. • Prevent viral RNA synthesis - target to the genetic material of the virus. Inhibit virus replication - target to key enzymes of the virus. • •
① SARS-CoV-2 Treatment Strategies ② Monoclonal antibody/convalescent plasma for ACE2: Prevent the virus into the host cell. 1 Camostat mesylate: Prevent SARS-CoV-2 into the cell by acting on TMPRSS2. 2 ③ Lopinavir-Ritonavir: Inhibition of protease activity of SARS-CoV-2. 3 4 Ribavirin- May inhibit mRNA capping. ④ RNA Synthesis Inhibitors: Inhibits SARS-CoV-2 RNA synthesis and replication. 5 RNA Synthesis Inhibitors ⑤ Neuraminidase Inhibitors (NAIs)-Interfere with the release of progeny influenza virus from infected host cells. 66 science.sciencemag.org/content/367/6485/1412 NAIs ⑥
Creative Biolabs’ SARS-CoV-2 Services In Vitro Diagnostic (IVD) Development Antibody & Immunoassay Development Services • Molecular Diagnostic Assay Development Services • SARS-CoV-2 Related Detection Kits • Drug Discovery Services Anti-SARS-CoV-2 Drug Discovery • SARS-CoV-2 Preclinical Research • SARS-CoV-2 Vaccine Discovery SARS-CoV-2 Preclinical Research •
Creative Biolabs’ SARS-CoV-2 Products SARS-CoV-2 MERS-CoV SARS-CoV Antibody Recombinant Proteins Plasmids PCR Primers & Probes Detection Kits Antibody Recombinant Proteins Plasmids Protein Expression Products Antibody Recombinant Proteins Plasmids Protein Expression Products Other Coronavirus RNA Extraction Kit Key Receptor ACE2 Antibody Recombinant Proteins Plasmids Protein Expression Products Antibody Recombinant Proteins Plasmids Protein Expression Products RNA Extraction Kits
Web: www.creative-biolabs.com Contact Us Email: info@creative-biolabs.com Address: 45-1 Ramsey Road, Shirley, NY 11967, USA